Identification by Microarrays of the Risks of Metastatic Relapse, Toxicity and Resistance to Adjuvant Chemotherapy in Completely Resected Non-small Cell Lung Cancer
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 192
- 试验地点
- 1
- 主要终点
- Determination of news microarrays profiles of NSCLC relapse risks
研究概览
简要总结
Description of new transcriptional profiles associated with risk of relapse and identification of specific sites of relapse in non-small cell lung cancer, toxicity and resistance to adjuvant chemotherapy in completely resected non-small cell lung cancer (NSCLC).
详细描述
- A first blood sample will be taken during the week before the operation. A second blood sample will be taken 4 to 8 weeks after the operation. And in case of relapse, a third sample will be taken. These samples are going to be stored in the collection of biological resources of Angers.
- Concerning the biopsy of the resected NSLCL, it will be sent to the collection of biological resources of Angers for conservation directly next to the surgery.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Major subject
- •Subject who received resection with primary non-small cell lung cancer at the University Hospital of Angers and whose tumor samples will be stored in collection of biological resources of University Hospital of Angers
- •A written inform consent.
排除标准
- •Under 18 year old;
- •Pregnant or nursing women;
- •Deprived of liberty;
- •Age under curatorship or guardianship;
- •Unable to consent person;
- •About not carrying a non-small cell lung cancer.
结局指标
主要结局
Determination of news microarrays profiles of NSCLC relapse risks
时间窗: At 10 years
The news microarrays profiles of NSCLC relapse risks will : * assessing the risk of relapse in patients undergoing resection of NSCLC (by knowing this risk, patients at highest risk of relapse would be treated as a priority, while avoiding treating patients with low risk) * assessing the risk of chemo-resistant tumor cells characters to optimize the choice of treatment to offer to the patient * assessing the prediction of sites most likely metastatic relapse to guide survey strategy.
次要结局
未报告次要终点